Oramed Pharmaceuticals

ORMPPhase 3

New York, United StatesFounded 2006oramed.com

Oramed Pharmaceuticals is focused on transforming the treatment of chronic diseases by developing oral versions of injectable therapies. Its core technology, the Protein Oral Delivery (POD™) platform, is designed to protect drug molecules as they pass through the gastrointestinal tract, enabling systemic absorption. The company's most advanced program is an oral insulin candidate, which has demonstrated safety and efficacy in multiple clinical trials and represents a significant market opportunity. Oramed is publicly traded and continues to explore applications of its platform beyond diabetes.

Market Cap

$138.9M

Founded

2006

Employees

50-100

Focus

Biotech

ORMP · Stock Price

USD 3.495.75 (-62.23%)

Historical price data

AI Company Overview

Technology Platform

The Protein Oral Delivery (POD™) platform is an integrated system designed to enable the oral administration of protein and peptide drugs through enteric protection, absorption enhancers, and enzyme inhibitors.

Pipeline Snapshot

16 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
ORMD-0801 QD + ORMD-0801 BD	Type 2 Diabetes Mellitus	Phase 3
ORMD-0801	T2DM (Type 2 Diabetes Mellitus)	Phase 3
ORMD-0801 8 mg + ORMD-0801 16 mg	Type 2 Diabetes Mellitus	Phase 3
ORMD-0801	Diabetes Mellitus, Type 2	Phase 3
ORMD-0801 (qd) + ORMD-0801 (bid) + ORMD-0801 (tid)	Type 2 Diabetes Mellitus	Phase 2

Funding History

Total raised: $67M

PIPE$50MUndisclosedMar 15, 2021

IPO$10MUndisclosedDec 20, 2007

Series A$5MUndisclosedJun 15, 2006

Seed$2MUndisclosedJun 15, 2002

Opportunities

The primary opportunity is the multi-billion dollar global diabetes market, where an oral insulin could capture significant share from injectables.

Success with the lead program would also validate the POD™ platform, creating opportunities to develop oral versions of other biologic drugs in endocrinology, immunology, and oncology.

Risk Factors

The key risks are clinical failure in Phase 3 trials, regulatory rejection, intense competition from established GLP-1 drugs, and the need for further dilutive financing.

The company's value is highly concentrated in a single late-stage asset.

Competitive Landscape

Oramed competes with other firms developing oral insulin (e.g., Diasome) but faces its strongest competition from highly effective injectable and oral GLP-1 drugs from Novo Nordisk and Eli Lilly. Its differentiation lies in its advanced clinical progress and comprehensive oral delivery platform.